<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428336</url>
  </required_header>
  <id_info>
    <org_study_id>1945</org_study_id>
    <nct_id>NCT01428336</nct_id>
  </id_info>
  <brief_title>Value of 25 mcg Cortrosyn Stimulation Test</brief_title>
  <acronym>25CST</acronym>
  <official_title>The Value of 25 mcg Cortrosyn Stimulation Test to Assess Adult HPA Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis of secondary AI is vital to prevent catastrophic events in patients. An optimal
      test should have a very low margin of error with high sensitivity and specificity, be easy
      and safe to administer, and have distinct cut off values. Both 1 ug and 250 ug doses have
      their limitations. Based on our experience over the past six years, we hypothesize that 25 ug
      ACTH stimulation test may eliminate some of the shortcomings of the LDST (1 ug) and SDST (250
      ug). This is supported by our preliminary data and the study by Oelkers et al, which looked
      at ACTH levels following various doses of cortrosyn injections.

      Therefore we propose a head to head comparison of 25 ug, 250 ug and 1 ug dose using ITT as
      gold standard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of two groups of adult patients 18 to 65 years of age. The first group
      (G1, n=10) included patients with hypothalamic/pituitary disease with at least one pituitary
      axis deficiency other than ACTH deficiency. The patients had the following diagnoses:
      acromegaly (n=1), prolactinoma (n=2), non-secreting pituitary macroadenomas (n=3), pituitary
      cholesterol granuloma (1), uncharacterized pituitary stalk lesion(1),recurrent null cell
      adenoma(1) and craniopharyngioma (n=1). The second group (G2, n=12) comprised healthy
      volunteers. The three CSTs and ITT were done in random order and separated by a median of 22
      days (range, 2 - 64 days) from each other. Cortisol levels were measured at 30 and 60 minute
      (min) during CSTs. A peak cortisol cut-off of 18 μg/dl was used as the pass criterion during
      ITT. The result of total cortisol levels during ITT were used to determine free cortisol
      cut-offs during CSTs and ITT. None of the patients had pituitary surgery within six weeks
      prior to enrollment and none of the women were on estrogen.

      Patients in G1 had to be on at least 3 months of stable hormone replacement for hormone
      deficiencies. All control subjects (G2) had normal TSH, free T4 and prolactin levels. All
      premenopausal women in the control group had a history of regular, age appropriate menses and
      none took birth control pills within 3 months of study entry. Postmenopausal subjects had
      appropriately elevated FSH concentration. All men in the control group had normal FSH and
      total testosterone levels.

      Exclusion criteria included: inability of subject to give an informed consent, pregnancy,
      patients with diabetes mellitus type 1 and type 2, any pituitary insult such as pituitary
      surgery in the past 6 weeks, elevated alanine aminotransferase (ALT) or aspartate
      aminotransferase (AST) more than 3 times the upper limit of normal, renal failure (defined as
      serum creatinine more than 2 mg/dl), history of malignancy in the last 5 years, severe acute
      illness and patients on opioid (fentanyl, oxycodone, hydrocodone, acetaminophen/hydrocodone)
      treatment. In addition, patients with a history of coronary artery disease, cerebrovascular
      disease, congestive heart failure, arrhythmias, or seizure disorder, were excluded due to the
      potential risk during ITT.

      Study procedures: Patients with HPA axis disorders and control subjects interested in the
      study were contacted by the research team for a screening interview. A complete medical
      history was obtained for each study participant. For female participants, a reproductive
      history was taken. All women in reproductive age group had a negative urine pregnancy test.

      All study participants were instructed to fast overnight for 12 hours prior to testing. Six
      patients were on glucocorticoid replacement and were instructed to hold their medication for
      24 hours prior to their dynamic testing. All the tests were conducted at the Clinical
      Research Unit on site at the Cleveland Clinic. The study was approved by the Cleveland Clinic
      Institutional Review Board. All subjects signed an informed consent.

      Cosyntropin Stimulation tests: The 250 µg cosyntropin vial was reconstituted with 1 ml of
      0.9% saline and used the same day. 25 µg cosyntropin was prepared by reconstituting the 250
      µg vial with 1 ml of 0.9% saline and withdrawing 0.1 ml for each injection. The unused
      reconstituted cosyntropin vials were discarded at the end of the day. 1 µg cosyntropin was
      prepared by diluting the 250 µg in 250ml of 0.9% saline and withdrawing 1ml for intravenous
      injection. Reconstituted solution for 1 µg dose was refrigerated and used for up to a month.
      During the CSTs, sFC and TC levels were drawn at baseline (t=0 min) and then at 30 and 60 min
      after 1µg (IV), 25 µg (IM) and 250µg (IM) cosyntropin doses.

      ITT: The test was initiated between 0800 and 0900 hrs, after an overnight fast. Regular human
      insulin 0.10 - 0.15 units /kg was administered intravenously, with target blood glucose less
      than 40 mg/dL. Additional insulin bolus was administered, if needed, to achieve the target
      glucose value. Administration of oral or intravenous dextrose was allowed if the subject
      developed signs of symptomatic hypoglycemia. Blood glucose levels were checked at 0, 15, 30,
      45, 60, 90 and 120 min and sFc and TC were drawn at 0, 30, 45, 60, 90 and 120 min.

      Assays: The screening labs for control subjects TSH, free T4, prolactin and complete
      metabolic profile and bedside blood glucose tests were done at the Cleveland Clinic lab. The
      screening labs for FSH, Testosterone, and samples of TC and sFC were analyzed at Quest
      Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA.

      TC was measured using Liquid Chromatography Mass Spectrometry (LCMS). The intra assay
      coefficient of variation (CV) were 3.0-4.6% at 15.9 and 202.7 µg /dl, respectively. The
      inter-assay CV were 4.8 and 7.6% at 15.2 and 189.9 µg /dl, respectively. sFC was measured
      using LCMS after separating bound and unbound cortisol by equilibrium dialysis. The intra
      assay CVs were 7.4 and 9.3 % at 0.36 and 2.17 µg /dl, respectively. The inter-assay CVs were
      9.4 and 9.8% at 0.36 and 2.17 µg/dl, respectively.

      Statistical analysis: Patient groups were compared on categorical factors using Pearson
      chi-square tests and Fisher exact tests. Continuous measures were evaluated using Wilcoxon
      rank sum tests. Sensitivity(SE) and specificity(SP) for each of the CSTs were estimated using
      optimal cut-offs from ROC curves, with respect to ITT as the gold standard. Youden's Index,
      which identifies the largest combination of SE and SP for each test was used to identify the
      optimal cut-off for each test. Tests were compared on SE and SP using McNemar's test.
      Pearson's correlation coefficient was used to measure the strength of association of peak
      cortisol levels among pairs of testing methods. Ninety-five percent confidence intervals were
      produced for all the correlation, SE, and SP estimates. Comparisons of the correlations were
      performed using the methods by Meng, Rosenthal, and Rubin (1992) to compare the correlations
      and calculate 95% confidence intervals for the difference among the tests [17]. Lower bounds
      of these intervals above a zero value was considered statistically significant evidence that
      the 25-µg test is a better test, while lower bounds at least as high as -0.15 was used to
      determine non-inferiority at those respective margins. Analyses were performed using R
      software (version 3.1; Vienna, Austria) and SAS software (version .3; Cary, NC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Every participant underwent the four interventional tests in random sequence</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pearson Correlation of the Total Cortisol Levels Between the ITT and CSTs</measure>
    <time_frame>1 hour for the CST interventions and 2 hour for the ITT interventions</time_frame>
    <description>Correlation of total cortisol levels of 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pearson Correlation of Free Cortisol Values During CSTs With ITT</measure>
    <time_frame>1 hour for the CST interventions and 2 hour for the ITT interventions</time_frame>
    <description>Correlation of free cortisol levels of 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Total Cortisol Values</measure>
    <time_frame>1 hour for the CST interventions and 2 hour for the ITT interventions</time_frame>
    <description>Peak total cortisol values during cortrosyn stimulation tests(CST)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>1 ug ACTH stimulation test</intervention_name>
    <description>1 ug cortrosyn dose</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>250 ug ACTH stimulation test</intervention_name>
    <description>ACTH stimulation test will be done using 250 ug cortrosyn dose</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>25 ug Cortrosyn stimulation test</intervention_name>
    <description>ACTH stimulation test using a 25 ug cortrosyn dose</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Insulin tolerance test</intervention_name>
    <description>subjects will undergo an insulin tolerance test</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypothalamic-pituitary-adrenal disorders

        Exclusion Criteria:

          -  under 18 or older than 65 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seenia Peechakara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Department of Endocrinology</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>September 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2011</study_first_posted>
  <results_first_submitted>November 30, 2016</results_first_submitted>
  <results_first_submitted_qc>April 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2017</results_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
    <mesh_term>Cosyntropin</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients</title>
          <description>Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</description>
        </group>
        <group group_id="P2">
          <title>Volunteers</title>
          <description>Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Every participant underwent three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</population>
      <group_list>
        <group group_id="B1">
          <title>Patients</title>
          <description>Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</description>
        </group>
        <group group_id="B2">
          <title>Volunteers</title>
          <description>Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pearson Correlation of the Total Cortisol Levels Between the ITT and CSTs</title>
        <description>Correlation of total cortisol levels of 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table</description>
        <time_frame>1 hour for the CST interventions and 2 hour for the ITT interventions</time_frame>
        <population>Correlation of total cortisol levels with 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table. The two groups of patients and volunteers were combined to get a full range of values for each intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients + Volunteers</title>
            <description>Every participant underwent three ACTH stimulation test and one Insulin tolerance test.</description>
          </group>
        </group_list>
        <measure>
          <title>Pearson Correlation of the Total Cortisol Levels Between the ITT and CSTs</title>
          <description>Correlation of total cortisol levels of 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table</description>
          <population>Correlation of total cortisol levels with 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table. The two groups of patients and volunteers were combined to get a full range of values for each intervention.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak 1 ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.57" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak 25 ug ACTH stimultion test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.69" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-minute 250ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.83" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-minute 250ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.82" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis comparing Peak 25ug CST correlation with ITT vs. Peak 1ug CST correlation with ITT</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority region of 0.15 for the difference in correlations is expected.</non_inferiority_desc>
            <param_type>Difference in correlation</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis comparing Peak 25ug CST correlation with ITT vs. Peak 250ug CST correlation with ITT</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority region of 0.15 for the difference in correlations is expected.</non_inferiority_desc>
            <param_type>Difference in correlation</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis comparing Peak 25ug CST correlation with ITT vs. 30-minute 250ug CST correlation with ITT</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority region of 0.15 for the difference in correlations is expected.</non_inferiority_desc>
            <param_type>Difference in correlation</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pearson Correlation of Free Cortisol Values During CSTs With ITT</title>
        <description>Correlation of free cortisol levels of 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table</description>
        <time_frame>1 hour for the CST interventions and 2 hour for the ITT interventions</time_frame>
        <population>Correlation of free cortisol levels with 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table. The two groups of patients and volunteers were combined to get a full range of values for each intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients + Volunteers</title>
            <description>Every participant underwent three ACTH stimulation test and one Insulin tolerance test.</description>
          </group>
        </group_list>
        <measure>
          <title>Pearson Correlation of Free Cortisol Values During CSTs With ITT</title>
          <description>Correlation of free cortisol levels of 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table</description>
          <population>Correlation of free cortisol levels with 1 ug, 25 ug and 250 ug cortrosyn stimulation test with Insulin Tolerance test is described in the outcome table. The two groups of patients and volunteers were combined to get a full range of values for each intervention.</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak 1ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.20" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak 25ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" lower_limit="0.39" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60- minute 250ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.74" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-minute 250ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.74" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis comparing Peak 25ug CST correlation with ITT vs. Peak 1ug CST correlation with ITT - free cortisol</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority region of 0.15 for the difference in correlations is expected.</non_inferiority_desc>
            <param_type>Difference in correlation</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis comparing Peak 25ug CST correlation with ITT vs. Peak 250ug CST correlation with ITT - free cortisol</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority region of 0.15 for the difference in correlations is expected.</non_inferiority_desc>
            <param_type>Difference in correlation</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis comparing Peak 25ug CST correlation with ITT vs. 30-minute 250ug CST correlation with ITT - free cortisol</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority region of 0.15 for the difference in correlations is expected.</non_inferiority_desc>
            <param_type>Difference in correlation</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Total Cortisol Values</title>
        <description>Peak total cortisol values during cortrosyn stimulation tests(CST)</description>
        <time_frame>1 hour for the CST interventions and 2 hour for the ITT interventions</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</description>
          </group>
          <group group_id="O2">
            <title>Volunteers</title>
            <description>Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Total Cortisol Values</title>
          <description>Peak total cortisol values during cortrosyn stimulation tests(CST)</description>
          <units>ug/dl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Insulin Tolerance Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="20.2" upper_limit="25.9"/>
                    <measurement group_id="O2" value="16.6" lower_limit="1.1" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" lower_limit="16.7" upper_limit="31.9"/>
                    <measurement group_id="O2" value="14.5" lower_limit="2.2" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="16.4" upper_limit="28.6"/>
                    <measurement group_id="O2" value="17.4" lower_limit="2.0" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min 250 ug ACTH stimulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="18.8" upper_limit="27.8"/>
                    <measurement group_id="O2" value="16.1" lower_limit="1.8" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min 250 ug ACTH simulation test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="21.9" upper_limit="31.5"/>
                    <measurement group_id="O2" value="19.1" lower_limit="2.4" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1ug Cortrosyn Dose Stimulation Test</title>
          <description>Subjects will undergo an ACTH stimulation test using a dose of 1 ug cotrosyn
ACTH stimulation test: 1 ug cortrosyn dose
1 ug cortrosyn test: Subjects will undergo an ACTH test using a 1 ug dose cortrosyn</description>
        </group>
        <group group_id="E2">
          <title>250 ug Cortrosyn Dose Stimulation Test</title>
          <description>Subjects will undergo an ACTH stimulation test using 250 ug cortrosyn dose
250 ug ACTH stimulation test: ACTH stimulation test will be done using 250 ug cortrosyn dose</description>
        </group>
        <group group_id="E3">
          <title>25 ug Cortrosyn Stimulation Test</title>
          <description>Subjects will undergo an ACTH stimulation test using a 25 ug cortosyn dose
25 ug Cortrosyn stimulation test: ACTH stimulation test using a 25 ug cortrosyn dose</description>
        </group>
        <group group_id="E4">
          <title>Insulin Tolerance Test</title>
          <description>Subjects will undergo an Insulin Tolerance Test
Insulin tolerance test: subjects will undergo an insulin tolerance test</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of participants Cortisol Binding globulin was not measured</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Seenia Peechakara</name_or_title>
      <organization>Cleveland Clinic Foundation</organization>
      <phone>216 4105901</phone>
      <email>peechas@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

